Company / Shareholders' Equity
Vertex Pharmaceuticals Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$18.7B
FY2025
5-year range
$10.1B / $18.7B
FY2021-FY2025
Trend
+13.7%
vs FY2024
Sector context
#7 of 213
Health Care
What the data says
Among 213 Health Care companies, Vertex Pharmaceuticals is in the top 3% for shareholders' equity. Improved from $17.6B to $18.7B over the past 2 years.
Based on SEC 10-K filings.
$18.7B in FY2025 with a 5-year CAGR of +16.5%. Top quartile in the Health Care sector.
Improved from $17.6B to $18.7B over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +10.3%
- 5-Year CAGR
- +16.5%
- 10-Year CAGR
- -
Sector benchmark
Top 3% in Health CareTop 3% of 213This company $18.7B Sector average $2.5B
▼
+632.3% above sector average
Key checks
Key Insights
- 5-year CAGR of +16.5%, indicating consistent growth.
- In FY2025, shareholders' equity increased 13.7% year-over-year.
- Ranks #7 out of 213 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2016.
Company context
Key Data Points
- Strong profit margin: 31.4%
- Strong return on equity: 21.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $18.7B | +13.7% |
| FY2024 | $16.4B | -6.7% |
| FY2023 | $17.6B | +26.4% |
| FY2022 | $13.9B | +37.7% |
| FY2021 | $10.1B | +16.3% |
| FY2020 | $8.7B | +42.8% |
| FY2019 | $6.1B | +37.2% |
| FY2018 | $4.4B | +118.6% |
| FY2017 | $2.0B | +75.4% |
| FY2016 | $1.2B | +23.0% |
As of FY2025 · SEC 10-K · Updated Mar 17, 2026